Eli Lilly and (LLY)
NYSE: LLY
· Real-Time Price · USD
824.15
30.05 (3.78%)
At close: May 02, 2025, 3:59 PM
824.00
-0.02%
After-hours: May 02, 2025, 05:52 PM EDT
3.78% (1D)
| Bid | 823.6 |
| Market Cap | 781.29B |
| Revenue (ttm) | 49B |
| Net Income (ttm) | 11.11B |
| EPS (ttm) | 12.31 |
| PE Ratio (ttm) | 66.95 |
| Forward PE | 26.87 |
| Analyst | Buy |
| Ask | 824 |
| Volume | 5,373,540 |
| Avg. Volume (20D) | 4,287,652.1 |
| Open | 825.12 |
| Previous Close | 794.10 |
| Day's Range | 807.59 - 831.53 |
| 52-Week Range | 677.09 - 972.53 |
| Beta | 0.50 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer ...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jun 1, 1972
Employees 47,000
Stock Exchange NYSE
Ticker Symbol LLY
Website https://www.lilly.com
Analyst Forecast
According to 26 analyst ratings, the average rating for LLY stock is "Buy." The 12-month stock price forecast is $1001, which is an increase of 21.46% from the latest price.
Stock ForecastsEarnings Surprise
Eli Lilly and has released their quartely earnings
on May 1, 2025:
3 days ago
-11.66%
Eli Lilly shares are trading lower after the compa...
Unlock content with
Pro Subscription
6 days ago
-0.82%
Eli Lilly shares are trading lower after HSBC downgraded the stock from Buy to Reduce and lowered the price target from $1,150 to $700.
